CompletedPhase 2NCT03917225
A Clinical Study to Evaluate the Effect of MIN-102 on the Progression of Friedreich's Ataxia in Male and Female Patients
Studying Friedreich ataxia
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Minoryx Therapeutics, S.L.
- Principal Investigator
- Alexandra Durr, PharmDICM, Groupe Hospitalier Pitié Salpêtrière, Paris, France, 75646
- Intervention
- MIN-102(drug)
- Enrollment
- 39 enrolled
- Eligibility
- 12-60 years · All sexes
- Timeline
- 2019 – 2020
Study locations (5)
- Hôpital Erasme-ULB, Brussels, Belgium
- ICM, Groupe Hospitalier Pitié Salpêtrière, Paris, France
- Universitätsklinikum RWTH, Aachen, Germany
- Hospital Sant Joan de Déu, Barcelona, Spain
- Hospital Universitario La Paz, Madrid, Spain
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT03917225 on ClinicalTrials.govOther trials for Friedreich ataxia
Additional recruiting or active studies for the same condition.
- RECRUITINGNCT06628687A Study to Learn How BIIB141 (Omaveloxolone) Affects the Health of Participants With Friedrich's Ataxia Who Took it During Pregnancy and/or During Breastfeeding and About the Health of Their BabiesBiogen
- RECRUITINGNCT06865482Clinical Course Of Disease In Participants With FA-CMLexeo Therapeutics
- RECRUITINGPHASE3NCT06953583A Study to Learn More About the Effects and Long-Term Safety of BIIB141 (Omaveloxolone) in Participants With Friedreich's Ataxia Aged 2 to 15 Years Old (BRAVE)Biogen
- RECRUITINGNCT07013292Efficacy of Omaveloxolone Treatment for Dysphagia in French Patients With Friedreich's AtaxiaCentre Hospitalier Universitaire de Nice
- RECRUITINGPHASE1, PHASE2NCT06874010A Multiple Ascending Dose Study of DT-216P2 in Patients With Friedreich's AtaxiaDesign Therapeutics, Inc.
- RECRUITINGNANCT06692296Efficacy of Stabilometric Platform to Improve Standing Balance in Patients With Friedreich's AtaxiaIRCCS Eugenio Medea
- RECRUITINGNCT06623890A Study to Learn More About the Long-Term Safety of BIIB141 (Omaveloxolone) in Participants With Friedreich's Ataxia Who Are Prescribed it by Their Own DoctorsBiogen
- RECRUITINGPHASE1NCT06054893A Study to Find Out How BIIB141 (Omaveloxolone) is Processed in the Body and to Learn More About Its Safety in Participants With Friedreich's Ataxia Aged 2 to 15 Years OldBiogen